Le‐Qun Li

机构：Guangxi Medical University, Guangxi Science and Technology Department, Shanghai Sixth People's Hospital, Tumor Hospital of Guangxi Medical University · ORCID：0000-0002-4143-2921

发表论文 160 篇 · 总被引 4683 次 · h-index 34

代表论文

• Real-World Data on the Diagnosis, Treatment, and Management of Hepatocellular Carcinoma in the Asia-Pacific: The INSIGHT Study (2023 · Liver Cancer · 被引 40)
• Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors (2023 · Frontiers in Oncology · 被引 25)
• Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC (2022 · Frontiers in Oncology · 被引 18)
• Clinical implications and biological features of a novel postoperative recurrent HCC classification: A multi‐centre study (2022 · Liver International · 被引 17)
• TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study (2024 · BMC Cancer · 被引 14)
• Conversion surgery for initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitor: A real-world observational study (2023 · Digestive and Liver Disease · 被引 14)